Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2532-2538

  Rakhmanina, Natella ^a,b   Van Den Anker, John ^a,b   Baghdassarian, Aline ^b   Soldin, Steven ^a,b,c   Williams, Keetra ^a   Neely, Michael N ^d  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR;

ADOLESCENT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MALE; MAXIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LINEAR MODELS; MALE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PROBABILITY; PROSPECTIVE STUDIES; PYRIMIDINONES;

EID: 67049173051     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01374-08     Document Type: Article

References (28)

1. Aarnoutse, R. E., C. P. W. G. M. Verweij-van Wissen, E. W. J. van Ewijk-Beneken Kolmer, E. W. Wuis, P. P. Koopmans, Y. A. Hekster, and D. M. Burger. 2002. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob. Agents Chemother. 46:884-886.
2. Anderson, B., K. Allegaert, and N. Holford. 2006. Population clinical pharmacology of children: modelling covariate effects. Eur. J. Pediatr. 165:819-829.
3. Beal, S. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504.
4. Bergshoeff, A., P. Fraaij, J. Ndagijimana, G. Verweel, N. Hartwig, T. Niehues, G. R. De, and D. Burger. 2005. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. J. Acquir. Immune. Defic. Syndr. 39:63-68.
5. Boffito, M., I. Arnaudo, R. Raiteri, S. Bonora, A. Sinicco, A. Di Garbo, H. E. Reynolds, P. G. Hoggard, D. J. Back, and G. Di Perri. 2002. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 16:2081-2083. (Pubitemid 35205274)
6. Boffito, M., P. G. Hoggard, D. J. Back, S. Bonora, A. Maiello, A. Lucchini, and G. Di Perri. 2002. Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with Kaposi's sarcoma. Antimicrob. Agents Chemother. 46:3684-3685.
7. Boxenbaum, H., and C. DiLea. 1995. First-time-in-human dose selection: allometric thoughts and perspectives. J. Clin. Pharmacol. 35:957-966.
8. Breilh, D., I. Pellegrin, A. Rouzes, K. Berthoin, F. Xuereb, H. Budzinski, M. Munck, H. Fleury, M. Saux, and J. Pellegrin. 2004. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 18:1305-1310. (Pubitemid 38822709)
9. Charpiat, B., V. Breant, C. Pivot-Dumarest, P. Maire, and R. Jelliffe. 1994. Prediction of future serum concentrations with Bayesian fitted pharmacokinetic models: results with data collected by nurses versus trained pharmacy residents. Ther. Drug Monit. 16:166-173.
10. Crommentuyn, K., B. Kappelhoff, J. Mulder, A. Mairuhu, E. van Gorp, P. Meenhorst, A. Huitema, and J. Beijnen. 2005. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br. J. Clin. Pharmacol. 60:378-389.
11. Droste, J. A. H., P. P. Koopmans, Y. A. Hekster, and D. M. Burger. 2005. TDM: therapeutic drug measuring or therapeutic drug monitoring? Ther. Drug Monit. 27:412-416. (Pubitemid 41098813)
12. Ghoshal, A. K., and S. J. Soldin. 2003. Improved method for concurrent quantification of antiretrovirals by liquid chromatography-tandem mass spectrometry. Ther. Drug Monit. 25:541-543.
13. Hsu, A., J. Isaacson, S. Brun, B. Bernstein, W. Lam, R. Bertz, C. Foit, K. Rynkiewicz, B. Richards, M. King, R. Rode, D. Kempf, G. Granneman, and E. Sun. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virusinfected patients. Antimicrob. Agents Chemother. 47:350-359.
14. Jelliffe, R. 1991. The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens, p. 922-924. In Proceedings of the Annual Symposium on Computer Applications in Medical Care.
15. Jullien, V., S. Urien, D. Hirt, C. Delaugerre, E. Rey, J. P. Teglas, P. Vaz, C. Rouzioux, M. L. Chaix, E. Macassa, G. Firtion, G. Pons, S. Blanche, and J. M. Treluyer. 2006. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob. Agents Chemother. 50:3548-3555.
16. Kline, M. W., S. Rugina, M. Ilie, R. F. Matusa, A. Schweitzer, N. R. Calles, and H. L. Schwarzwald. 2007. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy. Pediatrics 119:e1116-e1120. (Pubitemid 46715649)
17. Larrú, B., S. Resino, J. M. Bellón, M. I. de José, C. Fortuny, M. L. Navarro, M. D. Gurbindo, J. T. Ramos, P. Soler Palacín, J. A. Léon, M. Asensi, M. J. Mellado, and M. A. Muñoz- Fernández. 2008. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. J. Antimicrob. Chemother. 61:183-190.
18. Mosteller, R. 1987. Simplified calculation of body-surface area. N. Engl. J. Med. 317:1098.
19. Mu, S., and T. M. Ludden. 2003. Estimation of population pharmacokinetic parameters in the presence of non-compliance. J. Pharmacokinet. Pharmacodyn. 30:53-81.
20. Panel on Antiretroviral Guidelines for Adults and Adolescents. November 3, 2008. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, p. 1-139. Department of Health and Human Services, Washington, DC. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf.
21. Podzamczer, D., M. S. King, C. E. Klein, C. Flexner, C. Katlama, D. V. Havlir, S. L. Letendre, J. J. Eron, S. C. Brun, and B. Bernstein. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. HIV Clin. Trials 8:193-204. (Pubitemid 47327456)
22. Ramos, J. T., M. I. De José, J. Dueñas, C. Fortuny, R. González-Montero, M. J. Mellado, A. Mur, M. Navarro, C. Otero, I. Pocheville, M. A. Muñoz-Fernández, and E. Cabrero. 2005. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr. Infect. Dis. J. 24:867-873.
23. Resino, S., J. M. Bellón, and M. A. Muñoz-Fernández. 2006. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J. Antimicrob. Chemother. 57:579-582.
24. Saez-Llorens, X., A. Violari, C. Deetz, R. Rode, P. Gomez, E. Handelsman, S. Pelton, O. Ramilo, P. Cahn, E. Chadwick, U. Allen, S. Arpadi, M. Castrejon, R. Heuser, D. Kempf, R. Bertz, A. Hsu, B. Bernstein, C. Renz, and E. Sun. 2003. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 22:216-224.
25. Sun, H., E. Ette, and T. Ludden. 1996. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data. J. Pharmacokinet. Biopharm. 24:637-650.
26. Volosov, A., C. Alexander, L. Ting, and S. J. Soldin. 2002. Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry. Clin. Biochem. 35:99-103.
27. Wateba, M. I., E. Billaud, E. Dailly, P. Jolliet, and F. Raffi. 2006. Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients. HIV Med. 7:197-199. (Pubitemid 43337600)
28. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. 29 July 2008. Guidelines for the use of antiretroviral agents in pediatric HIV infection, p.1-134. http://aidsinfo.nih.gov/ ContentFiles/PediatricGuidelines.pdf.